Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059

Summary

Phase I, open-label, non-randomized study to evaluate safety of BC2059 administered intravenously to subjects with proven primary or recurrent desmoid tumor that is unresectable and symptomatic or progressive.

Timeline

Start

2018-07-15

Primary completion

2022-05-01

Completion

2022-05-01

Drugs

Indications